Financial Results

Quadient Publishes Q4 2026 Earnings Call Presentation

Stock market news /

$QDT Quadient Publishes Q4 2026 Earnings Call Presentation Key Takeaways Quadient S.A. has officially published its Q4 2026 Earnings Call Presentation, detailing financial performance for the period, per the company’s investor relations update. The presentation covers the fourth quarter of fiscal year 2026, providing insights into the company’s operational results and strategic outlook, as stated

Quadient Publishes Q4 2026 Earnings Call Presentation Read More »

$ZVRA Reports Q4 2025 Revenue Growth Amidst Pipeline Advancements

Stock market news /

Zevra Therapeutics, Inc. (ZVRA) reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant revenue growth and continued progress in its rare disease pipeline. The company posted **net product revenue of $15.2 million** for Q4 2025, primarily driven by robust sales of its attention-deficit/hyperactivity disorder (ADHD) treatment, **AZSTARYS®**.

$ZVRA Reports Q4 2025 Revenue Growth Amidst Pipeline Advancements Read More »

$IVVD Reports Strong Q4 2025 Revenue Beat, Positive VYD222 Update

Stock market news /

Key Takeaways Invivyd, Inc. (**$IVVD**) reported **Q4 2025 revenue** of **$25.3 million**, exceeding analyst consensus estimates of $23.5 million, per the Invivyd Q4 2025 Earnings Call Presentation. The company posted an adjusted **net loss** of **-$0.15 per share** for Q4, outperforming analyst expectations of a -$0.20 loss, according to the same presentation. Positive interim data

$IVVD Reports Strong Q4 2025 Revenue Beat, Positive VYD222 Update Read More »

$ATAI Exceeds Q4 2025 Revenue Estimates, Boosts Full-Year Guidance

Stock market news /

Key Takeaways Atea Pharmaceuticals, Inc. (ATAI) reported Q4 2025 revenue of $125 million, surpassing analyst consensus of $118 million, per the company’s earnings call presentation. Non-GAAP diluted earnings per share (EPS) reached $0.15, exceeding expectations of $0.10, according to internal company financial statements. The company initiated a Phase 3 clinical trial for its novel antiviral

$ATAI Exceeds Q4 2025 Revenue Estimates, Boosts Full-Year Guidance Read More »

$QBTS Reports 35% Q4 Revenue Growth Amid Strategic Quantum Investments

Stock market news /

$QBTS Reports 35% Q4 Revenue Growth Amid Strategic Quantum Investments Key Takeaways D-Wave Quantum Inc. (QBTS) announced Q4 2025 revenue of $5.8 million, marking a robust 35% increase year-over-year, primarily driven by strong performance in its cloud and professional services segments, per the Q4 2025 Earnings Call Transcript. Total bookings for the quarter reached $6.5

$QBTS Reports 35% Q4 Revenue Growth Amid Strategic Quantum Investments Read More »

$SIBN Reports Strong Q4 2025 Revenue Growth, Exceeding Expectations

Stock market news /

Key Takeaways Q4 2025 revenue reached $125.7 million, a 22% year-over-year increase, surpassing analyst consensus of $120 million, per the earnings call transcript. Non-GAAP gross margin improved to 82.5% in Q4 2025, up from 80.1% in the prior year period, according to the company’s financial statements discussed during the call. SI-BONE issued full-year 2026 revenue

$SIBN Reports Strong Q4 2025 Revenue Growth, Exceeding Expectations Read More »

UOB’s Q4 Profit Miss Signals Broader Banking Sector Headwinds

Stock market news /

Singapore’s United Overseas Bank (UOB) recently reported a significant miss on its fourth-quarter profit estimates, primarily driven by a substantial weakening in trading income. This unexpected performance from one of Southeast Asia’s largest lenders signals potential challenges within the regional banking sector, raising questions about broader economic pressures and market volatility for the period ending

UOB’s Q4 Profit Miss Signals Broader Banking Sector Headwinds Read More »